Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment
- 30 June 1999
- journal article
- clinical trial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 35 (6), 913-920
- https://doi.org/10.1016/s0959-8049(99)00028-3
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Factors affecting baseline quality of life in two international adjuvant breast cancer trialsBritish Journal of Cancer, 1998
- Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approachAnnals of Oncology, 1997
- Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90)European Journal of Cancer, 1997
- The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trialsSupportive Care in Cancer, 1993
- FormestaneDrugs of the Future, 1993
- Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trialEuropean Journal of Cancer, 1992
- Applications of global statistics in analysing quality of life dataStatistics in Medicine, 1990
- On the receiving end — III Measurement of quality of life during cancer chemotherapyAnnals of Oncology, 1990
- Improving the Quality of Life during Chemotherapy for Advanced Breast CancerThe New England Journal of Medicine, 1987
- On the receiving end—II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapyEuropean Journal of Cancer and Clinical Oncology, 1983